Society

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Conference, Cancer, Immunotherapy, New Drug Application, Integral, CLDN6, Insurance, Society, Trial of the century, IND, CD3, SITC, Context, Annual general meeting, Food

PHILADELPHIA, March 21, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the year ended December 31, 2023, and reported on recent and upcoming business highlights.

Key Points: 
  • “During the fourth quarter of 2023, Context continued to advance our lead clinical candidate, CTIM-76, a Claudin 6 ("CLDN6”) x CD3 bispecific antibody, toward a first-in-human clinical study.
  • The preclinical data further support CTIM-76’s differentiated product profile, including its potential to address limitations of first-generation CLDN6-targeted clinical-stage therapies,” said Martin Lehr, CEO of Context.
  • In November 2023, Context presented preclinical data at the SITC 38th Annual Meeting that demonstrated CTIM-76 was well tolerated and induced dose-proportional tumor regressions in xenograft models of CLDN6-positive cancer.
  • Context reported a net loss of $24.0 million for 2023, as compared to $14.8 million for the same period in 2022.

MiNK Reports Fourth Quarter and Year-End 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Pneumonia, Survival, Survival rate, NSCLC, Disease, Mink, Webcast, Patient, VV, Research, Gene, Cancer, Lung cancer, White lung, IND, Immunity, Society, Therapy, Paclitaxel, TCR, Cell, FDA, Nature Communications, Pharmaceutical industry

MiNK executives will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • MiNK executives will host a conference call and webcast at 8:30 a.m.
  • “In 2023, MiNK made significant strides in advancing our allogeneic iNKT cell programs, contributing to a growing body of clinical data that underscores the unique advantages of iNKTs and their pivotal role in immunity,” said Dr. Jennifer Buell, Chief Executive Officer and President at MiNK.
  • The study reports survival rates exceeding 70% among patients on mechanical ventilation and surpassing 80% among those receiving VV ECMO support.
  • These results stand in stark contrast to the 10% survival rate observed in the in-hospital control during the same period.

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
University, Sanofi, Therapeutic index, Growth, GSK plc, Rotman School of Management, Merck Serono, Immunotherapy, Partnership, Patient, SAN, Ipsen, Merck, Cancer, Faculty, Society, TU Dresden, Therapy, Institute of technology, SITC, University of Florida

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.
  • “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
  • Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors.
  • Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, SCTL, KNTE

Retrieved on: 
Wednesday, March 20, 2024
Fraud, Advertising, CDMO, Sale, Society, Security (finance)

If you are a Whole Earth shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Whole Earth shareholder, click here to learn more about your rights and options .
  • If you are a Societal CDMO shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

Retrieved on: 
Wednesday, March 20, 2024
Research, Harvard Medical School, Massachusetts General Hospital, Nicotine, Smoker, NIH, Society, Smoking, Safety, Bangladesh Technical Education Board, Annual general meeting, Tobacco

March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials.

Key Points: 
  • March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials.
  • Data collected include trial participants’ experiences, such as cravings and withdrawal symptoms, personal impact on overall health, and opinions on future use.
  • ORCA-V1 evaluated the effectiveness and safety of cytisinicline in users of nicotine e-cigarettes who wanted to quit vaping.
  • The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH.

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Retrieved on: 
Wednesday, March 20, 2024
Research, Teriparatide, Conference call, Conference, Obesity, Serum, SAN, Weight loss, Female, Adalimumab, Volunteering, Human, Society, Osteoporosis, Workforce, Expansion, Growth, GIP, Business operations, GLP, Animal, HC, Pharmaceutical industry

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • ET / 1:30 p.m. PT -
    SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the quarter and full year ended December 31, 2023 and provided a corporate update.
  • In February 2024, Rani announced RT-111 achieved high bioavailability and was well-tolerated, with no serious adverse events in humans, in a Phase 1 study.
  • In December 2023, Rani announced preclinical data demonstrating the transenteric delivery of an incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study.
  • In October 2023, Rani announced preclinical data from a 60-day, repeat oral-administration GLP safety study of the RaniPill capsule in healthy animals.

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 19, 2024
Research, OS, NCI, Mutation, EP4, Gene expression, Immunotherapy, RECIST, Patient, National Cancer Institute, Pembrolizumab, Society, AACR, Bevacizumab, Therapy, Nivolumab, ASCO, EP2, SITC, PFS, Liver cancer, FDA, Pharmaceutical industry

“2023 was a transformative year for Tempest.

Key Points: 
  • “2023 was a transformative year for Tempest.
  • We announced strong positive randomized data showing the benefit of TPST-1120 combination therapy compared to standard-of-care in first-line liver cancer,” said Stephen Brady, president and chief executive officer of Tempest.
  • Tempest ended the year with $39.2 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022.
  • Based on current cash and operating plan, Tempest expected to have sufficient resources to fund operations into the second quarter of 2025.

Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
Tuesday, March 19, 2024
Cloud, OSA, APLS, ASRS, Environment, Patient, Public, Inflammation, News, LLP, Retinal scan, DOJ, Complaint, CMI, Retinal vasculitis, EPA, Justice, Society, Retina, Safety, Paratriathlon, Physician, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.
  • Johnson Fistel LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Inspire Medical Systems, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCT

Retrieved on: 
Tuesday, March 19, 2024
AstraZeneca, Sale, Base, Lemon Popsicle, Brodsky, AZN, Society, CVR, Security (finance)

BALA CYNWYD, Pa., March 19, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., March 19, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the agreement, Societal will be acquired by CoreRx, Inc. (“CoreRx”) for $1.10 per share in cash.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.